Literature DB >> 27538418

The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease.

Audrey Maillet1, Paul Krack2, Eugénie Lhommée2, Elise Météreau3, Hélène Klinger4, Emilie Favre5, Didier Le Bars6, Emmanuelle Schmitt2, Amélie Bichon2, Pierre Pelissier2, Valérie Fraix2, Anna Castrioto2, Véronique Sgambato-Faure1, Emmanuel Broussolle7, Léon Tremblay1, Stéphane Thobois8.   

Abstract

SEE SCHRAG AND POLITIS DOI101093/AWW190 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: Apathy, which can occur separately or in combination with depression and anxiety, is one of the most frequently encountered neuropsychiatric symptoms in Parkinson's disease. Pathophysiological evidence suggests that parkinsonian apathy is primarily due to a mesolimbic dopaminergic denervation, but the role of the serotonergic alteration has never been examined, despite its well-known involvement in the pathogenesis of depression and anxiety. To fill this gap, we address here the pure model of de novo Parkinson's disease, without the confounding effects of antiparkinsonian treatment. Fifteen apathetic (Lille Apathy Rating Scale scores ≥ -21) and 15 non-apathetic (-36 ≤ Lille Apathy Rating Scale scores ≤ -22) drug-naïve de novo parkinsonian patients were enrolled in the present study and underwent detailed clinical assessment and positron emission tomography imaging, using both dopaminergic [(11)C-N-(3-iodoprop-2E-enyl)-2-beta-carbomethoxy-3-beta-(4-methylphenyl)-nortropane (PE2I)] (n = 29) and serotonergic [(11)C-N,N-dimethyl-2-(-2-amino-4-cyanophenylthio)-benzylamine (DASB)] (n = 27) presynaptic transporter radioligands. Apathetic parkinsonian patients presented higher depression (P = 0.0004) and anxiety (P = 0.004) scores - as assessed using the Beck Depression Inventory and the part B of the State-Trait Anxiety Inventory, respectively - compared to the non-apathetic ones - who were not different from the age-matched healthy subjects (n = 15). Relative to the controls, the non-apathetic parkinsonian patients mainly showed dopaminergic denervation (n = 14) within the right caudate nucleus, bilateral putamen, thalamus and pallidum, while serotonergic innervation (n = 15) was fairly preserved. Apathetic parkinsonian patients exhibited, compared to controls, combined and widespread dopaminergic (n = 15) and serotonergic (n = 12) degeneration within the bilateral caudate nuclei, putamen, ventral striatum, pallidum and thalamus, but also a specific bilateral dopaminergic disruption within the substantia nigra-ventral tegmental area complex, as well as a specific serotonergic alteration within the insula, the orbitofrontal and the subgenual anterior cingulate cortices. When comparing the two parkinsonian groups, the apathetic patients mainly displayed greater serotonergic alteration in the ventral striatum, the dorsal and the subgenual parts of the anterior cingulate cortices, bilaterally, as well as in the right-sided caudate nucleus and the right-sided orbitofrontal cortex. Regression analyses also revealed that the severity of apathy was moreover mainly related to specific serotonergic lesions within the right-sided anterior caudate nucleus and the orbitofrontal cortex, while the degree of both depression and anxiety was primarily linked to serotonergic disruption within the bilateral subgenual parts and/or the right dorsal part of the anterior cingulate cortex, without prominent role of the dopaminergic degeneration in the pathogenesis of these three non-motor signs. Altogether, these findings highlight a prominent role of the serotonergic degeneration in the expression of the neuropsychiatric symptoms occurring at the onset of Parkinson's disease.
© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  apathy; depression; dopamine; drug-naïve de novo Parkinson’s disease; serotonin

Mesh:

Substances:

Year:  2016        PMID: 27538418     DOI: 10.1093/brain/aww162

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  53 in total

1.  Depressive symptoms precede cognitive impairment in de novo Parkinson's disease patients: Analysis of the PPMI cohort.

Authors:  Jacob D Jones; Natalie E Kurniadi; Taylor P Kuhn; Sarah M Szymkowicz; Joseph Bunch; Elizabeth Rahmani
Journal:  Neuropsychology       Date:  2019-07-25       Impact factor: 3.295

Review 2.  Inhibitory dysfunction contributes to some of the motor and non-motor symptoms of movement disorders and psychiatric disorders.

Authors:  Marjan Jahanshahi; John C Rothwell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-04-19       Impact factor: 6.237

Review 3.  Serotonergic system, cognition, and BPSD in Alzheimer's disease.

Authors:  Saikat Chakraborty; Jack C Lennon; Sridhar A Malkaram; Yan Zeng; Daniel W Fisher; Hongxin Dong
Journal:  Neurosci Lett       Date:  2019-04-01       Impact factor: 3.046

4.  Is serotonin pathology a good biomarker in vivo for early Parkinson's disease?

Authors:  Celia Painous; Andres Perissinotti; Maria J Martí
Journal:  Ann Transl Med       Date:  2019-12

Review 5.  Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment.

Authors:  Stephane Thobois; Stephane Prange; Véronique Sgambato-Faure; Léon Tremblay; Emmanuel Broussolle
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-18       Impact factor: 5.081

Review 6.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  Anna Nagy; Anette Schrag
Journal:  J Neural Transm (Vienna)       Date:  2019-05-29       Impact factor: 3.575

Review 7.  Interaction Between Neuropsychiatric Symptoms and Cognitive Performance in Parkinson's Disease: What Do Clinical and Neuroimaging Studies Tell Us?

Authors:  Alexandru Hanganu; Oury Monchi
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-15       Impact factor: 5.081

Review 8.  Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states.

Authors:  Véronique Sgambato-Faure; Léon Tremblay
Journal:  J Neural Transm (Vienna)       Date:  2017-02-07       Impact factor: 3.575

9.  Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson's disease without dementia.

Authors:  Yoon-Sang Oh; Jean Hee Kim; Sang-Won Yoo; Eo-Jin Hwang; Chul Hyoung Lyoo; Kwang-Soo Lee; Joong-Seok Kim
Journal:  Neurol Sci       Date:  2020-10-31       Impact factor: 3.307

Review 10.  Parkinson disease-associated cognitive impairment.

Authors:  Dag Aarsland; Lucia Batzu; Glenda M Halliday; Gert J Geurtsen; Clive Ballard; K Ray Chaudhuri; Daniel Weintraub
Journal:  Nat Rev Dis Primers       Date:  2021-07-01       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.